

Biotage appoints Nomination Committee

A Nomination Committee consisting of members appointed by the three largest shareholders or group of shareholders has been formed for Biotage AB in accordance with the principles adopted by the annual general meeting held on 27 April 2023. The Nomination Committee shall, before the Annual General Meeting 2024, prepare proposal for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of fees and matters pertaining thereto.

The members of the Nominations Committee are:

- Kugan Sathiyanandarajah, Chairman of the Nomination Committee, appointed by Gamma Biosciences
- Patrik Jönsson, appointed by SEB Investment Management
- Kristian Åkesson, appointed by Didner & Gerge

Torben Jørgensen, Chairman of the Board of Biotage AB, is an acting member of the Nomination Committee.

Shareholders wishing to submit a proposal to the Nomination Committee may do so by sending email to the Chairman of the Board of Directors of Biotage AB at: <u>info@biotage.com</u>. Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than seven weeks in advance of the meeting.

The Annual General Meeting 2024 in Biotage will be held on Thursday, April 25, 2024 at 5:00pm CET in Uppsala. Shareholders who want to have a matter addressed at the Annual General Meeting 2024 must submit such a proposal to the same address as above (subject "Annual General Meeting 2024" for the e-mail and the letter, respectively) seven weeks in advance of the meeting at the latest.

Contacts

Tomas Blomquist, President and CEO Tel: 0705 23 01 63, tomas.blomquist@biotage.com



About Biotage

Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs appr. 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm. Website: www.biotage.com

Attachments

Biotage appoints Nomination Committee